News Category
Helus Pharma's appointments of Regina Donohue as Chief People Officer and Suresh Durgam to its Scientific Advisory Board signal strategic preparation ...
Helus Pharma reports progress in its Phase 3 program for HLP003 in major depressive disorder, with topline data expected in Q4 2026, and advances its ...
Helus Pharma's appointment of Michael Halstead as CEO signals strategic leadership to advance its Phase 3 depression program and potential commerciali...
Luke Van Der Veer's Website Rental Coaching program, which teaches local SEO for 'Rank and Rent' strategies, has expanded to 14 countries with 467 stu...
Ireland has banned electroconvulsive therapy for minors under its new Mental Health Act, a move praised by human rights groups as a significant step f...
Helus Pharma announced fiscal 2026 financial results and clinical pipeline updates, emphasizing the Phase 3 APPROACH trial for HLP003 in major depress...
Helus Pharma raised $50 million in a public offering to fund Phase 3 trials for its lead depression drug and other pipeline candidates, addressing unm...
Helus Pharma announced the pricing of a $50 million public offering to fund development of its HLP003 program for major depressive disorder, with Phas...
Helus Pharma announced that enrollment in its Phase 3 APPROACH trial for HLP003 has surpassed 86%, keeping the study on track for topline data in the ...
Helus Pharma announces its Chief Medical Officer will participate in a fireside chat at the H.C. Wainwright conference, highlighting the company's pro...
Craig Munro Wilson's 'Baptize America' examines the 1820 Campbell-Walker debate in forensic detail, arguing it was a pivotal moment that set American ...
Helus Pharma issued a correction to its partnership announcement with TARA Mind, clarifying the removal of references to Veterans Exploring Treatment ...
Helus Pharma appointed Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, enhancing its expertise in biotechnology, drug deli...
Helus Pharma announced the immediate resignation of CEO Michael Cola at the board's request, with Executive Chairman Eric So stepping in as interim CE...
Helus Pharma announced the appointment of Dr. Ken Kramer as senior vice president of medical affairs, bringing over 20 years of neuroscience medical a...
Europe's first data center powered by a microgrid has launched near Dublin, Ireland, offering a solution to rising energy demands by operating indepen...
Helus Pharma announced positive Phase 2 results for HLP004 as an adjunctive treatment for generalized anxiety disorder, showing significant symptom re...
Helus Pharma announced the appointment of Dr. Freda Lewis-Hall, a veteran biopharmaceutical leader with over 40 years of experience, to its board as c...
Helus Pharma announced publication of Phase 2a trial results in Nature Medicine showing that a single dose of SPL026 significantly reduced depressive ...
Helus Pharma reported Q3 2025 financial results highlighting progress in its HLP003 Phase 3 program for major depressive disorder and HLP004 Phase 2 p...
Helus Pharma announced the appointment of Michael Cola as CEO, effective immediately, as the company advances toward Phase 2 data for HLP004 and Phase...
Fully Promoted achieved systemwide sales growth, signed 57 new franchise agreements, and expanded into new international markets, reflecting a shift i...
Exit Factor, a franchise in business value enhancement and exit planning, plans to expand into New Zealand, Canada, Ireland, the Netherlands, and Aust...
YouTube is testing a new video-sharing and chat feature in Ireland and Poland, allowing users to share long videos, Shorts, and live streams directly ...
Hydromer announces a partnership with Avem Market Solutions to provide European and UK medical device developers with easier access to its specialty c...
